AOD-9604 vs MOTS-c: which one actually has data behind it

Last updated 2026-07-24

What are AOD-9604 and MOTS-c, in plain terms

AOD-9604 is a 15-amino-acid fragment of human growth hormone, built from the region of the hGH molecule (amino acids 176-191) that researchers believed was responsible for fat metabolism without the growth-promoting and blood-sugar side effects of full-length hGH. The idea, sometimes called the "lipolytic fragment" hypothesis, was that you could strip out the fat-burning signal and leave the rest behind. It was developed by an Australian biotech (Metabolic Pharmaceuticals) and went through actual Phase II human obesity trials in the early 2000s ^[1]. MOTS-c is a different animal entirely. It's a 16-amino-acid peptide encoded not in nuclear DNA but in the mitochondrial genome, specifically in a region of the 12S rRNA gene. It was discovered in 2015 and is classified as a "mitochondrial-derived peptide." The working theory is that MOTS-c acts as a stress-response signal between mitochondria and the nucleus, influencing insulin sensitivity and metabolic regulation, mostly studied through AMPK pathway activation in animal models. Both get marketed in fat-loss and "anti-aging" research-chemical circles. Both are unapproved for human use in the United States. But their evidence bases are not remotely equivalent, and that's the whole point of this comparison. If you want the full background on AOD-9604 specifically, including its trial history and dosing rationale, see our main AOD-9604 overview.

Does AOD-9604 have human trial data for fat loss?

Yes, and this is the fact that matters most. AOD-9604 went through Phase II clinical development for obesity, run by Metabolic Pharmaceuticals in Australia, and the peptide reached human testing at meaningful scale before development effectively stalled out. A 2004 review in Current Opinion in Investigational Drugs covers the metabolic rationale and trial status of AOD-9604 as an anti-obesity candidate ^[1]. The honest summary of that trial record: weight-loss outcomes in the AOD-9604 arms did not separate convincingly from placebo. This isn't a case of "the drug worked but the FDA rejected it for unrelated reasons." The efficacy signal itself was weak enough that development didn't progress to Phase III or approval. A broader 2006 survey of obesity drugs in clinical development situates AOD-9604 among a crowded field of candidates from that era, most of which also failed to produce durable, clinically meaningful weight loss ^[2]. There is no FDA-approved product containing AOD-9604. You can confirm that directly by searching Drugs@FDA, the FDA's own database of approved drug products ^[3]. Nothing named AOD-9604, or any fragment of hGH marketed under that designation, shows up there. So when someone tells you AOD-9604 "was proven in clinical trials," the accurate version is: it was tested in humans, and the fat-loss effect wasn't strong enough to separate from placebo. That's a meaningfully different claim, and it's the one the actual literature supports.

Does MOTS-c have human trial data for fat loss?

Not really, not yet, and not in any completed obesity trial that produces a comparable efficacy number. MOTS-c's foundational science, the mitochondrial-derived peptide biology, AMPK activation, and insulin sensitivity effects, comes overwhelmingly from mouse and cell-culture studies. There is no equivalent to the AOD-9604 Phase II obesity program for MOTS-c that we can point to with a specific human weight-loss outcome. This matters for how you weigh the two. AOD-9604's problem is that it was tested in people and the result was disappointing. MOTS-c's situation is different: it hasn't been tested in people at that scale, so there's no disappointing result to report, but there's also no positive human signal to point to either. A peptide with an interesting mouse mechanism and zero completed human obesity trials isn't more proven than one that failed a human trial. It's just untested in the way that actually matters for a person deciding whether to spend money on it. Be skeptical of any claim that MOTS-c is "clinically validated" for fat loss in humans. As of the current literature, that claim isn't supported by a completed, published human obesity trial with a fat-loss endpoint.

AOD-9604 vs MOTS-c: side-by-side comparison

Neither substance is on the FDA's 503A bulk drug substances list or the 503B list, the lists that determine what a compounding pharmacy can legally use in a compounded human drug product ^[4][5]. That's a real regulatory fact, not a technicality: under 21 U.S.C. 353a, compounded drugs get an exemption from full FDA approval requirements only when they meet specific conditions, including using bulk substances that appear on FDA's approved lists ^[7].

Why did AOD-9604 fail to beat placebo in obesity trials?

Nobody has a fully settled answer, but a few things are worth separating out. First, "failed to beat placebo" doesn't necessarily mean the fragment does nothing metabolically; animal and in vitro work on the 176-191 hGH fragment did show lipolytic (fat-releasing) activity in some models, which is why the trials happened in the first place ^[1]. The gap is between promising preclinical mechanism and a clinically meaningful, reproducible effect size in humans, and that gap is where most obesity drug candidates from that era died ^[2]. Second, the fragment approach itself is a real, defensible scientific idea, even if this particular fragment didn't pan out. The theory that hGH's growth-promoting effects and its metabolic effects might be separable at the peptide-fragment level is not crazy; it's the kind of hypothesis worth testing. It just didn't produce a drug. Third, weight loss trials are hard to win. Placebo response in obesity trials tends to be substantial on its own, lifestyle counseling that's often part of the trial protocol adds another confound, and effect sizes need to be fairly large to separate cleanly. A weak-to-moderate true effect can easily get lost in that noise, which is consistent with what happened here. What you shouldn't do is round "went through Phase II, didn't separate from placebo" up to "almost got approved" or down to "proven ineffective in all contexts." The honest read is: tested, not compelling, development stopped.

Which one is legal to buy and use in the US?

Neither is approved by the FDA, and neither is legally compoundable as a finished drug product under the standard pharmacy compounding pathway, at least not right now. The FDA's bulk drug substances lists for 503A (traditional compounding pharmacies) and 503B (outsourcing facilities) are the specific documents that determine what's allowed, and you can check them directly: the 503A list is at 21 CFR 216.23 ^[4] and the 503B list at 21 CFR 216.24 ^[5]. Neither AOD-9604 nor MOTS-c appears on either list as of the current regulations. Compounding pharmacies operate under 21 U.S.C. 353a, which requires (among other conditions) that the compounded substance come from an FDA-registered facility and, for many purposes, that the bulk substance be on an approved list or meet other narrow exceptions ^[7]. Anything sold as "research use only" and shipped to a consumer who then injects it isn't operating inside that framework at all; it's a separate, much less regulated market. FDA also maintains intended-use rules under 21 CFR 201.128 that matter here: if a product is marketed or labeled in a way that implies human therapeutic use (fat loss, anti-aging, etc.), that labeling itself can trigger drug regulation regardless of a "not for human consumption" disclaimer buried in fine print ^[8]. This is the regulatory tension that makes most gray-market AOD-9604 and MOTS-c products legally murky, more than ethically murky. If you're going to use either one, the more defensible path is a provider-reviewed process rather than an anonymous vial from a research-chemical site. If you want to see what that route looks like for AOD-9604 specifically, along with where to find AOD-9604 for sale through a reviewed channel, that's covered in our sourcing guide.

Does either peptide show up on a drug test?

For AOD-9604 specifically, there's a direct answer: a 2013 study in Drug Testing and Analysis found that AOD-9604 does not cross-react with, or influence, the WADA hGH isoform immunoassay, the standard test sports authorities use to detect growth hormone doping ^[6]. That means the fragment can't be caught by the same test used for full-length hGH, which is exactly why anti-doping labs had to develop separate detection methods for it. Those separate methods exist. Peptide-specific mass spectrometry approaches for detecting AOD-9604 and other small peptide drugs in doping controls are covered in multiple analytical chemistry papers, including a 2014 review of detection strategies for emerging non-approved peptide therapeutics ^[2], a 2014 review focused specifically on peptidic drug candidates in sports doping ^[5], and a 2016 method paper on direct urine injection and ion mobility mass spectrometry for screening peptides under 2 kDa, a size range that includes AOD-9604 ^[7]. We don't have equivalent, specific published detection-method data for MOTS-c in the sources reviewed for this article. If you're an athlete subject to testing, don't assume either peptide is invisible; anti-doping labs have been actively building out small-peptide detection capability for exactly this class of compound, and WADA prohibits growth hormone releasing factors and metabolic modulators broadly, more than by brand name.

What does the fragment rationale actually claim, and is it plausible?

The core claim behind AOD-9604 is that a specific 16-residue stretch of the hGH molecule carries the fat-metabolizing (lipolytic) signal separately from the growth-promoting signal carried by the rest of the molecule. If true, you could theoretically get fat-loss benefits without the side effects associated with full hGH, like insulin resistance, joint pain, and organ growth. This is a real, testable hypothesis, and it did get tested; that's the whole reason AOD-9604 exists as a compound anyone has heard of. The 2004 review of AOD-9604's metabolic profile documents the preclinical basis for this fragment-specific lipolytic activity ^[1]. But preclinical plausibility and human trial confirmation are different bars, and AOD-9604 cleared the first one without clearing the second. MOTS-c doesn't share this fragment-of-a-larger-hormone rationale at all; it's a peptide encoded by mitochondrial DNA, not a piece cut from a known hormone. Its rationale is about mitochondrial-nuclear signaling and cellular energy stress response. The two peptides get compared constantly in research-chemical marketing because they're both "metabolic peptides," but their underlying biological stories don't overlap much.

How does AOD-9604's evidence compare to newer, approved options?

This is probably the most useful framing for a reader trying to decide what to actually do. AOD-9604 is roughly two decades old as a research compound, went through real human trials, and the fat-loss signal wasn't strong enough to bring a drug to market. In that same stretch of time, an entirely different class of drugs, the GLP-1 receptor agonists (semaglutide, tirzepatide, and related compounds), went through large Phase III trials with clear, statistically separated weight-loss results and reached FDA approval for chronic weight management. That's the comparison that actually matters if your goal is documented, approved, human-trial-verified fat loss. AOD-9604 and MOTS-c are both, at best, mechanistically interesting research compounds sitting well behind that bar. Neither has anything close to a completed Phase III trial with a positive, FDA-reviewed outcome. None of this means AOD-9604 or MOTS-c are worthless as research tools, or that nobody should study them further. It means that if a seller or a forum thread describes either one as "clinically proven for fat loss," that phrase is doing a lot of unearned work. The Phase II record for AOD-9604 is public and reviewable ^[1][2]; go read it rather than take someone's word for what it says.

What are the safety and side-effect concerns for each?

For AOD-9604, the trial-era data suggests it was generally tolerated in the Phase II program without the classic hGH side effects like insulin resistance or fluid retention, which was actually the point of the fragment approach. But "tolerated in a formal trial with monitoring" is different from "safe to self-administer indefinitely from an unregulated source," and long-term safety data at scale doesn't exist the way it would for an approved drug. If you're researching side effects specifically, see our dedicated page on AOD-9604 side effects for a fuller rundown. For MOTS-c, published human safety data is limited, consistent with the fact that it hasn't gone through the same scale of human trial that AOD-9604 has. Recent reviews of peptide therapeutics in orthopedic and sports medicine contexts, including a 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews ^[9] and a 2026 Sports Medicine review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance ^[10], place compounds like these in the broader category of unapproved peptides where safety and efficacy data lag well behind marketing claims. Sourcing matters enormously here regardless of which peptide you're weighing. Unapproved, non-pharmaceutical-grade peptide products carry contamination, dosing accuracy, and purity risks that have nothing to do with the underlying molecule's biology. Whatever you decide about AOD-9604 or MOTS-c, dosing accuracy and reconstitution technique are worth getting right; our reconstitution guide and dosage calculator cover the practical side of that for AOD-9604 specifically.

So which one should you actually consider, if either?

If you're choosing purely on strength of evidence: AOD-9604 has the edge of actually having been tested in a real human obesity trial, even though the result was a disappointment. MOTS-c has a more elegant mechanistic story but hasn't cleared that same human testing bar yet, so there's no head-to-head human efficacy comparison to make. We're comparing a compound that was tested and underwhelmed to one that mostly hasn't been tested at all in the relevant population. Our honest read: neither belongs in the same conversation as GLP-1 drugs for anyone whose primary goal is documented, reliable fat loss. If you're going to use AOD-9604 anyway, out of research interest or because you've read the trial data yourself and want to draw your own conclusions, do it through a provider-reviewed process rather than an anonymous vial, and get your dosage and sourcing right rather than winging it. AOD-9604 Co reviews provider-fulfilled routes precisely because sourcing quality is the one variable in this whole picture you can actually control. If your interest in MOTS-c is research curiosity, know going in that you're working from mouse data, not a human trial record, and treat any claim of proven human fat-loss efficacy for it with real skepticism.

Frequently asked questions

What's the main difference between AOD-9604 and MOTS-c?

AOD-9604 is a fragment of human growth hormone that went through actual Phase II human obesity trials, where the fat-loss effect did not separate convincingly from placebo. MOTS-c is a mitochondrial-DNA-encoded peptide with mostly mouse and cell-culture data on metabolic signaling, without a comparable completed human obesity trial.

Is AOD-9604 FDA approved?

No. AOD-9604 does not appear in the FDA's Drugs@FDA database of approved drug products, and it is not on the FDA's 503A or 503B bulk drug substances lists that govern legal compounding pathways.

Is MOTS-c FDA approved?

No. Like AOD-9604, MOTS-c has no listing in the Drugs@FDA approved products database and does not appear on the FDA's 503A or 503B bulk drug substance lists, meaning there's no standard legal compounding pathway for it as a human drug.

Did AOD-9604 actually work in clinical trials?

It was tested in a Phase II human obesity program, and the fat-loss results did not clearly beat placebo. The peptide reached human testing, which is more than most research-chemical compounds can claim, but the efficacy signal wasn't strong enough to advance development toward approval.

Does MOTS-c have any human trial data at all?

Not in the form of a completed, published human obesity trial with a fat-loss endpoint comparable to AOD-9604's Phase II program. Most published MOTS-c evidence to date comes from mouse and cell-culture studies of mitochondrial and AMPK signaling.

Can AOD-9604 be detected in a drug test?

A 2013 study found AOD-9604 does not cross-react with the standard WADA hGH isoform immunoassay, so it isn't caught by that test. Anti-doping labs have since developed separate mass-spectrometry-based methods specifically to detect small peptides like AOD-9604 in urine.

Which peptide has better safety data, AOD-9604 or MOTS-c?

AOD-9604 has more human exposure data because it went through a formal Phase II trial program, though long-term safety outside that trial setting isn't well documented. MOTS-c's safety picture in humans is thinner, since most of its data comes from animal studies rather than monitored human trials.

Why did AOD-9604 fail to beat placebo for weight loss?

The exact reason isn't settled, but obesity trials generally have strong placebo response, and AOD-9604's true effect size, if any, appears to have been too small to separate cleanly from that noise. Animal studies showed lipolytic activity, but that didn't translate to a clear human efficacy result.

Is either AOD-9604 or MOTS-c as effective as GLP-1 drugs for weight loss?

No. GLP-1 receptor agonists went through large Phase III trials with clear, FDA-reviewed weight-loss results and approval for chronic weight management. Neither AOD-9604 nor MOTS-c has produced comparable human trial results or approval status.

Is it legal to buy AOD-9604 or MOTS-c in the US?

Neither is on FDA's approved bulk drug substances lists for compounding (21 CFR 216.23 for 503A, 21 CFR 216.24 for 503B), so there's no standard legal compounding pathway for either as a finished human drug product right now. Products sold as research chemicals operate outside that regulated framework entirely.

What is the fragment rationale behind AOD-9604?

AOD-9604 is built from amino acids 176-191 of human growth hormone, a region researchers believed carried hGH's fat-metabolizing signal separately from its growth-promoting effects. The hypothesis was testable and did reach human trials, but the trials didn't confirm a strong enough fat-loss effect to bring a drug to market.

Should I use AOD-9604 or MOTS-c for fat loss?

Based on the human trial record, neither has strong evidence supporting reliable fat loss in people. AOD-9604 at least reached a real Phase II trial and underwhelmed; MOTS-c mostly hasn't been tested in humans that way. If proven fat loss is your goal, approved GLP-1 medications have a far stronger evidence base.

Sources

1. Current Opinion in Investigational Drugs, 2004 (PMID 15134286): Covers AOD-9604's metabolic/lipolytic rationale and Phase II obesity trial development; fat-loss effect did not separate convincingly from placebo.
2. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Reviews therapeutic peptides including unapproved candidates in orthopedic applications, safety and efficacy challenges.
3. Sports Medicine, 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance.
4. Drug Testing and Analysis, 2013 (PMID 24124033): AOD-9604 does not cross-react with or influence the WADA hGH isoform immunoassay used in doping tests.
5. Current Opinion in Investigational Drugs, 2006 (PMID 16625817): Surveys obesity drugs in clinical development in the mid-2000s, situating AOD-9604 among candidates that largely failed to show durable efficacy.
6. Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): Describes analytical detection approaches developed for emerging non-approved peptide therapeutics including AOD-9604.
7. Methods and Findings in Experimental and Clinical Pharmacology, 2003/2005 (PMID 14685303, 14571286, 15834452): Documents gateways to clinical trials process relevant to AOD-9604-era obesity drug development.
8. eCFR, 21 CFR 216.23: Lists the bulk drug substances approved for use in 503A pharmacy compounding; AOD-9604 and MOTS-c do not appear on it.
9. eCFR, 21 CFR 216.24: Lists the bulk drug substances approved for use in 503B outsourcing facility compounding; AOD-9604 and MOTS-c do not appear on it.
10. Cornell Law School Legal Information Institute, 21 U.S.C. 353a: Defines the legal conditions under which pharmacy compounding is exempt from standard FDA drug approval requirements.
11. eCFR, 21 CFR 201.128: Defines how a product's labeling or marketed intended use can trigger drug regulation regardless of disclaimers.
12. FDA, Drugs@FDA database: Confirms no FDA-approved drug product exists under the name AOD-9604 or MOTS-c.